
Baxdrostat Shows Significant BP Reduction in Phase III BaxHTN Trial
WILMINGTON, Del., September 01, 2025 — Positive full results from the BaxHTN Phase III trial showed baxdrostat demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) at two doses […]